Tag: BioTech, Healthcare&Pharm, Clinical Trials
WholisticResearch Reveals the Best Nootropics of 2023
LONDON, Aug 18, 2023 – (ACN Newswire) – WholisticResearch, a leading authority in the realm of cognitive enhancement research, has recently unveiled its list of the top nootropic supplements for 2023. [more…]
NSI Lab Solutions Launches MicroVive: The Only 30-Day Rehydration Fluid for Microbiological Cultures
Raleigh, NC, June 14, 2023 – (ACN Newswire) – NSI Lab Solutions is excited to introduce MicroVive(TM), the only 30-day rehydration fluid for freezer storage of microbiological-certified reference materials. MicroVive is [more…]
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
HONG KONG, Apr 14, 2023 – (ACN Newswire) – Essex Bio-Technology Ltd. (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. (“Majeton”), [more…]
TrialWire Patient Recruitment Platform Launches AI Pre-recruit to Cut Recruitment Time by 50%
ADELAIDE, AUS, Apr 11, 2023 – (ACN Newswire) – The award-winning TrialWire(TM) Patient Recruitment Platform, the most secure and rapid digital patient recruitment solution to reverse failing recruitment, today announced the [more…]
Essex Bio-Technology Announces 2022 Annual Financial Results
HONG KONG, Mar 8, 2023 – (ACN Newswire) – Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022. [more…]
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
HONG KONG, Feb 10, 2023 – (ACN Newswire) – Essex Bio-Technology Ltd (“Essex” or the “Group”, 1061.HK) today announced that the first patient in the United States (US) was dosed in [more…]
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
SYDNEY, AU, Feb 10, 2023 – (ACN Newswire) – Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics [more…]
Novotech Acquires European CRO, Strengthens Global Operations
SINGAPORE, Jan 12, 2023 – (ACN Newswire) – Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the [more…]
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
SINGAPORE, Jan 12, 2023 – (ACN Newswire) – Novotech, the leading Asia Pacific-centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversight and strategic regulatory [more…]
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 – (ACN Newswire) – HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, [more…]
Novotech is Gold Sponsor at Biotech Showcase 2023
SYDNEY, AU, Dec 20, 2022 – (ACN Newswire) – Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023. Novotech CEO Dr. John [more…]
Data Shows 50% of New Trials Have Sites in Asia Pacific
SYDNEY, AU, Dec 15, 2022 – (ACN Newswire) – Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of [more…]
